Proteasomal Regulation of Caspase-8 in Cancer Cell Apoptosis

Overview

Journal Apoptosis

Publisher Springer

Date 2013 Mar 5

PMID 23456622

Citations 13

Authors

Michael V Fiandalo

Steven R Schwarze

Natasha Kyprianou

Affiliations

Soon will be listed here.

Abstract

Previous studies demonstrated that proteasome inhibition sensitizes TRAIL resistant prostate cancer cells to TRAIL-mediated apoptosis via stabilization of the active p18 subunit of caspase-8. The present study investigated the impact of proteasome inhibition on caspase-8 stability, ubiquitination, trafficking, and activation in cancer cells. Using caspase-8 deficient neuroblastoma (NB7) cells for reconstituting non-cleavable mutant forms of caspase-8, we demonstrated that the non-cleavable forms of caspase-8 are capable of inducing apoptosis comparably to wild-type caspase-8, in response to proteasome inhibitor and GST-TRAIL. Moreover in the LNCaP human prostate cancer cells, caspase-8 polyubiquitination occurs after TRAIL stimulation and caspase-8 processing. Subcellular fractionation analysis revealed caspase-8 activity in both cytosol and plasma membrane fractions in both NB7 reconstituted caspase-8 cell lines, as well the LNCaP prostate cancer cells. The present results suggest that caspase-8 stabilization through proteasome inhibition leads to reactivation of the extrinsic pathway of apoptosis and identify E3 ligase mediating caspase-8 polyubiquitination, as a novel molecular target. Inhibition of this E3 ligase in combination with TRAIL towards restoring apoptosis signaling activation may have potential therapeutic significance in resistant tumors.

Citing Articles

The Dual Roles of Human γδ T Cells: Anti-Tumor or Tumor-Promoting.

Li Y, Li G, Zhang J, Wu X, Chen X Front Immunol. 2021; 11:619954.

PMID: 33664732 PMC: 7921733. DOI: 10.3389/fimmu.2020.619954.

Relationship between the Regulation of Caspase-8-Mediated Apoptosis and Radioresistance in Human THP-1-Derived Macrophages.

Yoshino H, Konno H, Ogura K, Sato Y, Kashiwakura I Int J Mol Sci. 2018; 19(10).

PMID: 30322167 PMC: 6214119. DOI: 10.3390/ijms19103154.

Cell Death Pathways: a Novel Therapeutic Approach for Neuroscientists.

Morris G, Walker A, Berk M, Maes M, Puri B Mol Neurobiol. 2017; 55(7):5767-5786.

PMID: 29052145 PMC: 5994217. DOI: 10.1007/s12035-017-0793-y.

DR5-Cbl-b/c-Cbl-TRAF2 complex inhibits TRAIL-induced apoptosis by promoting TRAF2-mediated polyubiquitination of caspase-8 in gastric cancer cells.

Xu L, Zhang Y, Qu X, Che X, Guo T, Li C Mol Oncol. 2017; 11(12):1733-1751.

PMID: 28972304 PMC: 5709619. DOI: 10.1002/1878-0261.12140.

Hsp83 loss suppresses proteasomal activity resulting in an upregulation of caspase-dependent compensatory autophagy.

Choutka C, DeVorkin L, Go N, Hou Y, Moradian A, Morin G Autophagy. 2017; 13(9):1573-1589.

PMID: 28806103 PMC: 5612217. DOI: 10.1080/15548627.2017.1339004.

References

Cursi S, Rufini A, Stagni V, Condo I, Matafora V, Bachi A . Src kinase phosphorylates Caspase-8 on Tyr380: a novel mechanism of apoptosis suppression. EMBO J. 2006; 25(9):1895-905. PMC: 1456929. DOI: 10.1038/sj.emboj.7601085. View

Wang J, Chun H, Wong W, Spencer D, Lenardo M . Caspase-10 is an initiator caspase in death receptor signaling. Proc Natl Acad Sci U S A. 2001; 98(24):13884-8. PMC: 61136. DOI: 10.1073/pnas.241358198. View

Zhang X, Zhang L, Yang H, Huang X, Otu H, Libermann T . c-Fos as a proapoptotic agent in TRAIL-induced apoptosis in prostate cancer cells. Cancer Res. 2007; 67(19):9425-34. PMC: 2941899. DOI: 10.1158/0008-5472.CAN-07-1310. View

Krueger A, Schmitz I, Baumann S, Krammer P, Kirchhoff S . Cellular FLICE-inhibitory protein splice variants inhibit different steps of caspase-8 activation at the CD95 death-inducing signaling complex. J Biol Chem. 2001; 276(23):20633-40. DOI: 10.1074/jbc.M101780200. View

Scott F, Fuchs G, Boyd S, Denault J, Hawkins C, Dequiedt F . Caspase-8 cleaves histone deacetylase 7 and abolishes its transcription repressor function. J Biol Chem. 2008; 283(28):19499-510. PMC: 2443678. DOI: 10.1074/jbc.M800331200. View

Christian P, Fiandalo M, Schwarze S . Possible role of death receptor-mediated apoptosis by the E3 ubiquitin ligases Siah2 and POSH. Mol Cancer. 2011; 10:57. PMC: 3115909. DOI: 10.1186/1476-4598-10-57. View

Zhang L, Ren X, Alt E, Bai X, Huang S, Xu Z . Chemoprevention of colorectal cancer by targeting APC-deficient cells for apoptosis. Nature. 2010; 464(7291):1058-61. PMC: 3425353. DOI: 10.1038/nature08871. View

Medema J, Scaffidi C, Kischkel F, Shevchenko A, Mann M, Krammer P . FLICE is activated by association with the CD95 death-inducing signaling complex (DISC). EMBO J. 1997; 16(10):2794-804. PMC: 1169888. DOI: 10.1093/emboj/16.10.2794. View

Bhalla S, Balasubramanian S, David K, Sirisawad M, Buggy J, Mauro L . PCI-24781 induces caspase and reactive oxygen species-dependent apoptosis through NF-kappaB mechanisms and is synergistic with bortezomib in lymphoma cells. Clin Cancer Res. 2009; 15(10):3354-65. PMC: 2704489. DOI: 10.1158/1078-0432.CCR-08-2365. View

10.

Martin D, Siegel R, Zheng L, Lenardo M . Membrane oligomerization and cleavage activates the caspase-8 (FLICE/MACHalpha1) death signal. J Biol Chem. 1998; 273(8):4345-9. DOI: 10.1074/jbc.273.8.4345. View

11.

Deveraux Q, Roy N, Stennicke H, Van Arsdale T, Zhou Q, Srinivasula S . IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhibition of distinct caspases. EMBO J. 1998; 17(8):2215-23. PMC: 1170566. DOI: 10.1093/emboj/17.8.2215. View

12.

Algeciras-Schimnich A, Shen L, Barnhart B, Murmann A, Burkhardt J, Peter M . Molecular ordering of the initial signaling events of CD95. Mol Cell Biol. 2001; 22(1):207-20. PMC: 134211. DOI: 10.1128/MCB.22.1.207-220.2002. View

13.

Prevarskaya N, Skryma R, Shuba Y . Ca2+ homeostasis in apoptotic resistance of prostate cancer cells. Biochem Biophys Res Commun. 2004; 322(4):1326-35. DOI: 10.1016/j.bbrc.2004.08.037. View

14.

Christian P, Thorpe J, Schwarze S . Velcade sensitizes prostate cancer cells to TRAIL induced apoptosis and suppresses tumor growth in vivo. Cancer Biol Ther. 2008; 8(1):73-80. DOI: 10.4161/cbt.8.1.7132. View

15.

Plasilova M, Zivny J, Jelinek J, Neuwirtova R, cermak J, Necas E . TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors. Leukemia. 2002; 16(1):67-73. DOI: 10.1038/sj.leu.2402338. View

16.

Yeung B, Huang D, Sinicrope F . PS-341 (bortezomib) induces lysosomal cathepsin B release and a caspase-2-dependent mitochondrial permeabilization and apoptosis in human pancreatic cancer cells. J Biol Chem. 2006; 281(17):11923-32. DOI: 10.1074/jbc.M508533200. View

17.

Mitsiades C, Treon S, Mitsiades N, Shima Y, Richardson P, Schlossman R . TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications. Blood. 2001; 98(3):795-804. DOI: 10.1182/blood.v98.3.795. View

18.

Koschny R, Holland H, Sykora J, Haas T, Sprick M, Ganten T . Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res. 2007; 13(11):3403-12. DOI: 10.1158/1078-0432.CCR-07-0251. View

19.

Wilson T, McLaughlin K, McEwan M, Sakai H, Rogers K, Redmond K . c-FLIP: a key regulator of colorectal cancer cell death. Cancer Res. 2007; 67(12):5754-62. DOI: 10.1158/0008-5472.CAN-06-3585. View

20.

Nencioni A, Hua F, Dillon C, Yokoo R, Scheiermann C, Cardone M . Evidence for a protective role of Mcl-1 in proteasome inhibitor-induced apoptosis. Blood. 2004; 105(8):3255-62. DOI: 10.1182/blood-2004-10-3984. View